[Innate defence against tumor cells: the killer cell IKDC].
IKDC (IFN-producing killer dendritic cell) is a new and rare subset of dendritic cells recently identified in mice. IKDCs possess both natural killer and dendritic cell markers. They can lyse tumor target cells without prior activation through several different lysis pathways : perforin, TRAIL or IFNgamma-induced antiangiogenesis. Iinterleukin-2 combined with Gleevec(trade mark) can not only induce activation and proliferation of IKDC in vitro but also leads to their accumulation at sites of tumors in vivo in mice. These observations should pave the way for clinical trials in patients with cancer in a near future.
Chaput
Nathalie
N
U805 Inserm, Institut Gustave-Roussy, Université Paris XI.
Taieb
Julien
J
Zitvogel
Laurence
L
D019264:Adoptive Transfer / Q000379:methods; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002465:Cell Movement / Q000276:immunology; D003110:Colonic Neoplasms / Q000188:drug therapy; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D000068877:Imatinib Mesylate; D007111:Immunity, Cellular; D007113:Immunity, Innate; D007157:Immunologic Surveillance / Q000276:immunology; D007372:Interferons / Q000096:biosynthesis*; D007376:Interleukin-2 / Q000008:administration & dosage; D007694:Killer Cells, Natural / Q000166:cytology / Q000276:immunology*; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000517:prevention & control; D051379:Mice; D010641:Phenotype; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage
D000970:Antineoplastic Agents; D001549:Benzamides; D007376:Interleukin-2; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D007372:Interferons